In hypertrophic cardiomyopathy (HCM), beta-blockers (BBs) and non-dihydropyridine calcium channel blockers (particularly verapamil) are both used to manage symptoms such as dyspnea, chest pain, and palpitations. In clinical guidelines, BBs are the first-line agents for most patients with HCM and verapamil is an alternative for patients with contraindications or intolerance to BBs[1,2]. Some studies have evaluated their efficacy and safety, although direct head-to-head comparisons are scarce and large randomized trials are missing[3,4].
